FIT OF FLUXES OF SUNSCREENS AND OTHER COMPOUNDS 191 water (and hence SMI) (15) and increasing the MWs (28) should decrease the topical ab- sorption of sunscreens and other compounds and lead to safer sunscreen formulations. In addition, because of their similar dependencies on solubilities in a lipid solvent, OCT, and in a polar solvent, PG:AQ, 30:70 or water, and inversely on MWs, there was a reason- ably substantial correlation between fl uxes through human skin in vivo and fl uxes through silicone membranes similar to that which had previously been observed with fl uxes through human skin in vitro (22). Thus, fl ux values of sunscreens and other compounds from PG:AQ, 30:70, through human skin in vivo were accurately calculated from the coeffi cients of the fi t of their solubilities in the lipid OCT and water, their MW and their fl ux values from water through silicone membrane to the RS equation (23). Finally, it should be noted that these results are consistent with the results from other databases fi t to RS equation although the coeffi cients to the independent variables may be slightly different depending on the membrane and VEH. Regardless of whether the da- tabase comprised MW, lipid, and aqueous solubilities and fl uxes through human skin in vitro from water, n = 185, r2 = 0.84 (4), fl uxes through human skin in vivo from MO, n = 10, r2 = 0.93 (29), fl uxes through hairless mouse skin from water, n = 32, r2 = 0.90 (30), fl uxes through hairless mouse skin from isopropyl myristate, n = 42, r2 = 0.94 (2), the fi t to the RS equation is good. REFERENCES (1) M. S. Roberts, S. E. Cross, and M. A. Pellett, “Skin transport,” in Dermatological and Transdermal Formu- lations, K. A. Walters, Ed. (Marcel Dekker, New York, 2002), pp. 89–195. (2) W. J. Roberts and K. B. Sloan, Correlation of aqueous and lipid solubilities with fl ux for prodrugs of 5-fl uorouracil, theophylline and 6-mercaptourine: a Potts-Guy approach, J. Pharm Sci., 88, 515–532 (1999). (3) S. Majumdar, J. Thomas, S. Wasdo, and K. B. Sloan, The effect of water solubility of solutes on their fl ux through human skin in vitro, Int. J. Pharm., 329, 25–36 (2007). (4) J. Juntunen, S. Majumdar, and K. B Sloan, The effect of water solubility of solutes on their fl ux through human skin in vitro: A prodrug database integrated into the extended Flynn database, Int. J. Pharm., 351, 92–103 (2008). (5) G. L. Flynn, “Physicochemical determinates of skin absorption,” in Principles of Route-to-Route Extrapola- tion for Risk Assessment, J. R. Gerrity and C. J. Henry, Eds. (Elsevier, Amsterdam, 1990), pp. 93–127. (6) K. B. Sloan, S. A. M. Koch, and K. G Siver, Mannich base derivatives of theophylline and 5-fl uorouracil: Synthesis, properties and topical delivery characteristics, Int. J. Pharm., 21, 251–264 (1984). (7) K. B. Sloan, Prodrugs for dermal delivery, Ad. Drug Delivery Rev., 3, 67–101 (1989). (8) K. B. Sloan, “Functional group considerations in the development of prodrug approaches to solving topical delivery problems,” in Prodrugs: Topical and Ocular Drug Delivery K. B. Sloan, Ed. (Marcel Dekker, New York, 1992), pp. 17–116. (9) F. P. Bonina, L. Montenegro, P. DeCapraris, E. Bousquet, and S. Tirendi, 1-Alkylazacycloalkan-2-one esters as prodrugs of indomethacin for improved delivery through human skin, Int. J. Pharm., 77, 21–29 (1991). (10) J. Rautio, T. Nevalainen, H. Taipale, J. Vepsalainen, J. Gynther, K. Laine, and T. Jarvinen, Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy- 2-naphthyl)propionic acid (Naproxen) for topical delivery, J. Med. Chem., 43, 1489–1494 (2000). (11) M. A. Kiselev, N. Y. Ryabova, A. M. Balagurov, S. Dante, T. Hauss, J. Zbytovska, S. Wartewig, and R. H. H. Neubert, New insights into the structure and hydration of a stratum corneum lipid model membrane by neutron diffraction, Eur. Biophys. J., 34, 1030–1040 (2005). (12) K. B. Sloan, S. C. Wasdo, and S. Majumdar, “Topical and transdermal delivery using prodrugs: Mecha- nism of enhancement,” in Prodrugs and Targeted Delivery, J. Rautio, Ed. (Wiley-VCH, Weinheim, 2011), pp. 153–179. (13) A. S. Michaels, S. K. Chandrasekaran, and J. E. Shaw, Drug permeation through human skin: Theory and in vitro experimental measurement, Am. Inst. Chem. Eng., 21, 985–996 (1975).
JOURNAL OF COSMETIC SCIENCE 192 (14) G. B. Kasting, R. L. Smith, and E. R. Cooper, “Effect of lipid solubility and molecular size in percutane- ous absorption,” in Pharmacology and the Skin, B. Schroot and H. Shaefer, Eds. (Karger, Basel, 1987), Vol 1, pp. 138–153. (15) K. B. Sloan, S. C. Wasdo, and J. Rautio, Design for optimized topical delivery: Prodrugs and a para- digm change, Pharm. Res., 23, 2729–2747 (2006). (16) Q. Zhang, J. E. Grice, P. Li, O. G. Jepps, G. J. Wang, and M. S. Roberts, Skin solubility determines maximum transdermal fl ux for similar size molecules, Pharm. Res., 26, 1974–1985 (2009). (17) Q. Zhang, P. Li, and M. S. Roberts, Maximum transepidermal fl ux for similar size phenolic compounds is enhanced by solvent uptake into the skin, J. Control. Rel., 154, 50–57 (2011). (18) K. M. Hanson, E. Gratton, and C. J. Bardeen, Sunscreen enhancement of UV-induced reactive oxygen species in the skin, Free Radic. Biol. Med., 41, 1205–1212 (2006). (19) I. Karlson, L. Hilllerstrom, A. Stenfeldt, J. Martensson, and A. Borje, Photodegradation of dibenzoyl- methanes: Potential cause of photocontact allergy to sunscreens, Chem. Res. Toxicol., 22, 1881–1892 (2009). (20) A. Varvaresou, Percutaneous absorption of organic sunscreens, J. Cosmet. Derm., 5, 53–57 (2006). (21) U. Hagedorn-Lewke and B. C. Lippold, Absorption of sunscreens and other compounds through human skin in vivo: Derivation of a method to predict maximum fl uxes, Pharm. Res., 12, 1354–1360 (1995). (22) S.C. Wasdo, J. Juntunen, H. Devarajan, and K. B. Sloan, A correlation of fl ux through a silicone mem- brane with fl ux through hairless mouse skin and human skin in vitro, Int. J. Pharm., 373, 62–67 (2009). (23) S. C. Wasdo, J. Juntunen, H. Devarajan, T. Murray, D. Nickels, S. Singh, T. Shanks, K. Ulmer, and K. B. Sloan, Modeling of fl ux through silicone membranes from water, Eur. J. Pharm. Sci., 34, 321–332 (2008). (24) M. A. Pellett, A. C. Watkinson, J. Hadgraft, and K. R. Brain, Comparison of permeability data from traditional diffusion cells and ATR-FTIR spectroscopy. Part I. Synthetic membranes, Int. J. Pharm., 154, 205–215 (1997). (25) J. N. Twist and J. L. Zatz, Infl uence of solvents on paraben permeation through idealized skin model membranes, J. Soc. Cosmet. Chem., 37, 429–444 (1986). (26) J. N. Twist and J. L. Zatz, Membrane-solvent-solute interaction in a model permeation system, J. Pharm. Sci., 77, 536–540 (1998). (27) K. B. Sloan, S. A. M. Koch, K. G. Siver, and F. P. Flowers, The use of solubility parameters of drug and vehicles to predict fl ux, J. Invest. Dermatol., 87, 244–252 (1986). (28) B. M. Magnusson, Y. G. Anissimov, S. E. Cross, and M. S. Roberts, Molecular size as the main determi- nant of solute maximum fl ux across the skin, J. Invest. Dermatol., 122, 993–999 (2004). (29) W. J. Roberts and K. B. Sloan, Application of the transformed Potts-Guy equation to in vivo human skin data, J. Pharm. Sci., 90, 1318–1323 (2001). (30) S. C. Wasdo, J. Juntunen, H. Devarajan, and K. B. Sloan, A comparison of the fi t of fl ux through hairless mouse skin from water data to three model equations, Int. J. Pharm, 366, 65–73 (2009).
Previous Page Next Page